Russell Investments Group Ltd. Has $4.15 Million Stock Position in Janux Therapeutics, Inc. $JANX

Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 15,117.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 153,848 shares of the company’s stock after purchasing an additional 152,837 shares during the period. Russell Investments Group Ltd.’s holdings in Janux Therapeutics were worth $4,154,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC raised its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after acquiring an additional 1,574 shares during the last quarter. US Bancorp DE raised its holdings in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after acquiring an additional 1,658 shares during the last quarter. FNY Investment Advisers LLC raised its holdings in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock worth $66,000 after acquiring an additional 2,425 shares during the last quarter. Finally, KBC Group NV acquired a new stake in shares of Janux Therapeutics in the 1st quarter worth about $66,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price on the stock. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday. They issued an “overweight” rating and a $42.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $86.90.

Janux Therapeutics Stock Up 1.3%

Janux Therapeutics stock opened at $24.30 on Friday. Janux Therapeutics, Inc. has a twelve month low of $21.97 and a twelve month high of $71.71. The firm has a 50 day moving average price of $24.51 and a 200-day moving average price of $27.79. The company has a market capitalization of $1.46 billion, a P/E ratio of -13.50 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). Equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.